Developer docs
API playgroundTry for free, no card

Search company profiles

Equillium

Full company profile

uuid0000xww

Namestring
Equillium
Legal namestring
Equillium, Inc.
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Equillium is a clinical-stage biotechnology company founded in 2017 (IPO on NASDAQ as EQ in October 2018) that develops novel immunomodulatory therapeutics for severe autoimmune and inflammatory disorders with high unmet medical need. The company's pipeline comprises three core programs: EQ504, a potent and selective aryl hydrocarbon receptor (AhR) modulator acquired through the May 2025 Ariagen acquisition, designed for targeted local delivery in ulcerative colitis and inflammatory lung diseases; EQ302, an oral bi-specific cytokine inhibitor targeting IL-15 and IL-21 derived from a proprietary Multi-Cytokine Inhibitor Platform of structured-domain stapled peptides acquired through the February 2022 Bioniz Therapeutics acquisition; and itolizumab, a first-in-class monoclonal antibody targeting the CD6-ALCAM signaling pathway.

Equillium operates from its headquarters in La Jolla, California and a research facility in San Diego. The company has 11-50 employees and is led by co-founder Bruce Steel (CEO), co-founder Stephen Connelly (President/CSO), Chief Operating Officer Christine Zedelmayer, Chief Development Officer Snehal Naik (appointed to lead clinical development across the pipeline, including the EQ504 program), and SVP Finance Penny Tom. The board is chaired by Daniel Bradbury.

The business model is pre-revenue clinical development with licensing/partnering as the primary monetization mechanism. Equillium historically generated revenue through an Asset Purchase Agreement with Ono Pharmaceutical, which produced $41.1M in FY2024 but wound down to zero in FY2025. The company has raised approximately $85M in 2025-2026 through two private placements ($50M led by ADAR1/Janus Henderson in August 2025; $35M led by RA Capital in March 2026), holds ~$61.3M in cash (March 2026), and guides cash runway into 2029. With no commercialized products, future revenue is expected to come from strategic partnerships, licensing, or product commercialization, including plans for EQ504 (Phase 1 in mid-2026) and progression of EQ302 in celiac disease.

Short descriptiontext

Equillium is a clinical-stage biotechnology company developing immunomodulatory therapeutics (EQ504 AhR modulator, EQ302 multi-cytokine inhibitor, itolizumab anti-CD6 mAb) for severe autoimmune and inflammatory disorders with high unmet medical need.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immunomodulatory therapeutics, autoimmune disease drug development, clinical-stage biotechnology, cytokine inhibitor platform, inflammatory disorder therapeutics
Industry4 codes
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-stage Immunotherapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Asset Transactions
TypeLicensing Royalties
Description

Pre-revenue clinical stage company. Previously generated $41.1 million in revenue in 2024 from Asset Purchase Agreement with Ono Pharmaceutical for clinical studies and asset sale. Revenue dropped to zero in 2025 due to wind-down of clinical studies and completion of the Asset Purchase Agreement. Future revenue potential from drug development partnerships, licensing deals, or product commercialization.

biospace.com
2Pipeline Development Partnerships
TypeLicensing Royalties
Description

Strategic partnerships for co-development and commercialization of drug candidates. The company evaluates further advancement of EQ302 for GI indications including celiac disease, potentially through partnering arrangements.

equilliumbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Equillium is a clinical-stage biotechnology company developing novel immunomodulatory therapeutics for severe autoimmune and inflammatory disorders with high unmet medical need. Its pipeline includes EQ504 (an aryl hydrocarbon receptor modulator entering Phase 1 for ulcerative colitis), EQ302 (an oral multi-cytokine IL-15/IL-21 inhibitor in discovery for celiac disease), and itolizumab (a first-in-class anti-CD6 monoclonal antibody). The company intends to commercialize these candidates through strategic partnerships and licensing deals with large pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Phase 1 proof-of-mechanism study for EQ504 planned for mid-2026 with data expected approximately six months thereafter
+1 more record
Product overview1 text field

Equillium is a clinical-stage biotechnology company developing novel immunomodulatory therapeutics for severe autoimmune and inflammatory disorders. The company's portfolio includes three main product candidates: EQ504 (a potent and selective AhR modulator for ulcerative colitis and inflammatory lung diseases), EQ302 (an oral bi-specific IL-15/IL-21 inhibitor for gastrointestinal and skin diseases), and itolizumab (a monoclonal antibody targeting the CD6-ALCAM pathway). These programs are supported by a proprietary Multi-Cytokine Inhibitor Platform technology that enables rational design of peptide-based cytokine inhibitors.

Product and service3 records
1EQ504
CategoryClinical-stage small molecule immunomodulator
Description

A potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action. EQ504 is designed for targeted, local delivery via enteric coating for ulcerative colitis and other gastrointestinal diseases, or inhaled formulations for inflammatory lung diseases. It maintains barrier function, promotes tissue repair and regeneration, and regulates resident immune cells with anti-inflammatory responses.

2EQ302
CategoryClinical-stage stapled peptide immunomodulator
Description

A first-in-class selective bi-specific cytokine inhibitor targeting IL-15 and IL-21, two cytokines central to T and B cell activity that exhibit biological synergy driving aggressive inflammatory responses in gastrointestinal and skin diseases. EQ302 is orally delivered as a structured-domain stapled peptide with increased stability and permeability in the GI tract.

3Itolizumab
CategoryClinical-stage monoclonal antibody immunomodulator
Description

A clinical-stage, first-in-class immune-modifying monoclonal antibody that targets the CD6-ALCAM signaling pathway to selectively downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining balanced immune response. Indicated for graft-versus-host disease and other autoimmune and inflammatory conditions.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-16
Description

Equillium acquired Bioniz Therapeutics including two clinical-stage assets and a proprietary platform. Transaction involved consideration of over 5.7 million shares of Equillium's common stock. The acquisition expanded Equillium's immunology pipeline.

2Ono Pharmaceutical
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Prior strategic partnership involving Asset Purchase Agreement that generated $41.1 million in revenue in 2024. The partnership was completed/wound down in 2025.

equilliumbio.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage immunology biotech developing oral therapeutics for inflammatory diseases. Highly comparable stage, size, and therapeutic focus; Equillium's CDO Snehal Naik was previously SVP and Head of Clinical Development at Ventyx.

TypeDirect peer
Description

Clinical-stage biotech developing immunology therapeutics leveraging novel biology (respiratory and inflammation). Similar stage, similar mechanism-driven approach to inflammation; co-founder Connelly previously worked at aTyr.

TypeBroad incumbent
Description

Clinical-stage antibody-focused biotech with programs in inflammatory/immunology indications (e.g., rosnilimab, ANB032). Comparable mechanism of antibody-based immunomodulation, larger market cap, broader pipeline.

TypeDirect peer
Description

Clinical-stage biotech developing immunology therapies (now part of Sanofi). Similar size and development-stage profile focused on autoimmune and inflammatory indications with high unmet need.

5Morphic Holding
TypeDirect peer
Description

Clinical-stage biotech developing oral integrin therapeutics for autoimmune diseases including UC and IBD. Direct overlap with Equillium's UC focus via EQ504; comparable development stage and immunology platform play.

TypeEmerging player
Description

Late-clinical-stage biotech with programs in rare inflammatory diseases and GI conditions. Comparable small-cap clinical-stage profile and therapeutic area overlap in inflammatory conditions.

7Bristol-Myers Squibb
TypeBroad incumbent
Description

Major pharma with Zeposia (ozanimod) approved for UC. Represents the competitive landscape Equillium's UC programs would face; provides a benchmark for large-pharma commercial scale in the indication.

TypeBroad incumbent
Description

Major pharma with Humira, Skyrizi, and Rinvoq across autoimmune indications including UC. Represents the dominant competitive force in inflammatory bowel disease that any Equillium UC entrant must address.

TypeOthers
Description

Acquired by Celgene (now BMS) for $7.2B largely on the strength of ozanimod in UC/MS — represents the successful exit path that clinical-stage UC-focused biotechs like Equillium aspire to and that CEO Bruce Steel helped invest in at BioMed Ventures.

10Ono Pharmaceutical
TypeOthers
Description

Japanese pharma that was Equillium's prior strategic partner via Asset Purchase Agreement (generated $41.1M revenue in 2024). Represents the licensing/partnering counterparty archetype for clinical-stage assets like EQ504.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Equillium

Clinical-stage Immunotherapeuticsequilliumbio.com

Equillium is a clinical-stage biotechnology company developing immunomodulatory therapeutics (EQ504 AhR modulator, EQ302 multi-cytokine inhibitor, itolizumab anti-CD6 mAb) for severe autoimmune and inflammatory disorders with high unmet medical need.

What Equillium does

Equillium is a clinical-stage biotechnology company founded in 2017 (IPO on NASDAQ as EQ in October 2018) that develops novel immunomodulatory therapeutics for severe autoimmune and inflammatory disorders with high unmet medical need. The company's pipeline comprises three core programs: EQ504, a potent and selective aryl hydrocarbon receptor (AhR) modulator acquired through the May 2025 Ariagen acquisition, designed for targeted local delivery in ulcerative colitis and inflammatory lung diseases; EQ302, an oral bi-specific cytokine inhibitor targeting IL-15 and IL-21 derived from a proprietary Multi-Cytokine Inhibitor Platform of structured-domain stapled peptides acquired through the February 2022 Bioniz Therapeutics acquisition; and itolizumab, a first-in-class monoclonal antibody targeting the CD6-ALCAM signaling pathway.

Equillium operates from its headquarters in La Jolla, California and a research facility in San Diego. The company has 11-50 employees and is led by co-founder Bruce Steel (CEO), co-founder Stephen Connelly (President/CSO), Chief Operating Officer Christine Zedelmayer, Chief Development Officer Snehal Naik (appointed to lead clinical development across the pipeline, including the EQ504 program), and SVP Finance Penny Tom. The board is chaired by Daniel Bradbury.

The business model is pre-revenue clinical development with licensing/partnering as the primary monetization mechanism. Equillium historically generated revenue through an Asset Purchase Agreement with Ono Pharmaceutical, which produced $41.1M in FY2024 but wound down to zero in FY2025. The company has raised approximately $85M in 2025-2026 through two private placements ($50M led by ADAR1/Janus Henderson in August 2025; $35M led by RA Capital in March 2026), holds ~$61.3M in cash (March 2026), and guides cash runway into 2029. With no commercialized products, future revenue is expected to come from strategic partnerships, licensing, or product commercialization, including plans for EQ504 (Phase 1 in mid-2026) and progression of EQ302 in celiac disease.

Equillium firmographics

Firmographics
Name
Equillium
Legal name
Equillium, Inc.
Website
https://equilliumbio.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Equillium is a clinical-stage biotechnology company developing immunomodulatory therapeutics (EQ504 AhR modulator, EQ302 multi-cytokine inhibitor, itolizumab anti-CD6 mAb) for severe autoimmune and inflammatory disorders with high unmet medical need.
Ownership category
akta.pro rank

Equillium industry classification

Industry
Product category
Clinical-stage Immunotherapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Immunomodulatory therapeutics
  • Autoimmune disease drug development
  • Clinical-stage biotechnology
  • Cytokine inhibitor platform
  • Inflammatory disorder therapeutics

Where Equillium is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Equillium business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Licensing and Asset Transactions: Pre-revenue clinical stage company. Previously generated $41.1 million in revenue in 2024 from Asset Purchase Agreement with Ono Pharmaceutical for clinical studies and asset sale. Revenue dropped to zero in 2025 due to wind-down of clinical studies and completion of the Asset Purchase Agreement. Future revenue potential from drug development partnerships, licensing deals, or product commercialization.
  2. Pipeline Development Partnerships: Strategic partnerships for co-development and commercialization of drug candidates. The company evaluates further advancement of EQ302 for GI indications including celiac disease, potentially through partnering arrangements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Equillium product offering

Product offering

Core offering

Equillium is a clinical-stage biotechnology company developing novel immunomodulatory therapeutics for severe autoimmune and inflammatory disorders with high unmet medical need. Its pipeline includes EQ504 (an aryl hydrocarbon receptor modulator entering Phase 1 for ulcerative colitis), EQ302 (an oral multi-cytokine IL-15/IL-21 inhibitor in discovery for celiac disease), and itolizumab (a first-in-class anti-CD6 monoclonal antibody). The company intends to commercialize these candidates through strategic partnerships and licensing deals with large pharmaceutical companies.

Product overview

Equillium is a clinical-stage biotechnology company developing novel immunomodulatory therapeutics for severe autoimmune and inflammatory disorders. The company's portfolio includes three main product candidates: EQ504 (a potent and selective AhR modulator for ulcerative colitis and inflammatory lung diseases), EQ302 (an oral bi-specific IL-15/IL-21 inhibitor for gastrointestinal and skin diseases), and itolizumab (a monoclonal antibody targeting the CD6-ALCAM pathway). These programs are supported by a proprietary Multi-Cytokine Inhibitor Platform technology that enables rational design of peptide-based cytokine inhibitors.

Differentiator

Problem solved

Functional benefit

Products and services

  • EQ504 A potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action. EQ504 is designed for targeted, local delivery via enteric coating for ulcerative colitis and other gastrointestinal diseases, or inhaled formulations for inflammatory lung diseases. It maintains barrier function, promotes tissue repair and regeneration, and regulates resident immune cells with anti-inflammatory responses.
  • EQ302 A first-in-class selective bi-specific cytokine inhibitor targeting IL-15 and IL-21, two cytokines central to T and B cell activity that exhibit biological synergy driving aggressive inflammatory responses in gastrointestinal and skin diseases. EQ302 is orally delivered as a structured-domain stapled peptide with increased stability and permeability in the GI tract.
  • Itolizumab A clinical-stage, first-in-class immune-modifying monoclonal antibody that targets the CD6-ALCAM signaling pathway to selectively downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining balanced immune response. Indicated for graft-versus-host disease and other autoimmune and inflammatory conditions.

Quantifiable outcome

  • Phase 1 proof-of-mechanism study for EQ504 planned for mid-2026 with data expected approximately six months thereafter
  • +1 more outcomes

Companies that use Equillium

Customer profile

Segments1 record

Ideal customer profiles1 record

Equillium technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Equillium partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and major.

  • Bioniz TherapeuticscoreStrategic or Co-development Partner · 16 February 2022Equillium acquired Bioniz Therapeutics including two clinical-stage assets and a proprietary platform. Transaction involved consideration of over 5.7 million shares of Equillium's common stock. The acquisition expanded Equillium's immunology pipeline.
  • Ono PharmaceuticalmajorStrategic or Co-development PartnerPrior strategic partnership involving Asset Purchase Agreement that generated $41.1 million in revenue in 2024. The partnership was completed/wound down in 2025.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Equillium competitors and assessment

Company assessment

Direct peers

  • Ventyx Biosciences: Clinical-stage immunology biotech developing oral therapeutics for inflammatory diseases. Highly comparable stage, size, and therapeutic focus; Equillium's CDO Snehal Naik was previously SVP and Head of Clinical Development at Ventyx.
  • aTyr Pharma: Clinical-stage biotech developing immunology therapeutics leveraging novel biology (respiratory and inflammation). Similar stage, similar mechanism-driven approach to inflammation; co-founder Connelly previously worked at aTyr.
  • Provention Bio: Clinical-stage biotech developing immunology therapies (now part of Sanofi). Similar size and development-stage profile focused on autoimmune and inflammatory indications with high unmet need.
  • Morphic Holding: Clinical-stage biotech developing oral integrin therapeutics for autoimmune diseases including UC and IBD. Direct overlap with Equillium's UC focus via EQ504; comparable development stage and immunology platform play.

Broad incumbents

  • AnaptysBio: Clinical-stage antibody-focused biotech with programs in inflammatory/immunology indications (e.g., rosnilimab, ANB032). Comparable mechanism of antibody-based immunomodulation, larger market cap, broader pipeline.
  • Bristol-Myers Squibb: Major pharma with Zeposia (ozanimod) approved for UC. Represents the competitive landscape Equillium's UC programs would face; provides a benchmark for large-pharma commercial scale in the indication.
  • AbbVie: Major pharma with Humira, Skyrizi, and Rinvoq across autoimmune indications including UC. Represents the dominant competitive force in inflammatory bowel disease that any Equillium UC entrant must address.

Emerging players

  • Soligenix: Late-clinical-stage biotech with programs in rare inflammatory diseases and GI conditions. Comparable small-cap clinical-stage profile and therapeutic area overlap in inflammatory conditions.

Others

  • Receptos: Acquired by Celgene (now BMS) for $7.2B largely on the strength of ozanimod in UC/MS — represents the successful exit path that clinical-stage UC-focused biotechs like Equillium aspire to and that CEO Bruce Steel helped invest in at BioMed Ventures.
  • Ono Pharmaceutical: Japanese pharma that was Equillium's prior strategic partner via Asset Purchase Agreement (generated $41.1M revenue in 2024). Represents the licensing/partnering counterparty archetype for clinical-stage assets like EQ504.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Equillium social profiles

Digital presence

Equillium financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Equillium leadership team

Management profile

Number of profiles

Profiles5 records

Equillium funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Equillium M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Equillium

What does Equillium do?

Equillium is a clinical-stage biotechnology company developing novel immunomodulatory therapeutics for severe autoimmune and inflammatory disorders with high unmet medical need. Its pipeline includes EQ504 (an aryl hydrocarbon receptor modulator entering Phase 1 for ulcerative colitis), EQ302 (an oral multi-cytokine IL-15/IL-21 inhibitor in discovery for celiac disease), and itolizumab (a first-in-class anti-CD6 monoclonal antibody). The company intends to commercialize these candidates through strategic partnerships and licensing deals with large pharmaceutical companies.

Is Equillium a public or private company?

Equillium is a public company. It is classified as public and is currently operating.

When was Equillium founded?

Equillium was founded in 2017. It employs 11 to 50 people.

Where is Equillium based?

Equillium is headquartered in San Diego, United States, in the North America region.

How does Equillium make money?

Two revenue lines are on record. Licensing and Asset Transactions are the primary driver. The others are pipeline Development Partnerships.

Who are Equillium's main competitors?

Direct peers on record are Ventyx Biosciences, aTyr Pharma, Provention Bio and Morphic Holding. Broad incumbents are AnaptysBio, Bristol-Myers Squibb and AbbVie. Soligenix is listed as an emerging player. Others are Receptos and Ono Pharmaceutical.

Does Equillium have an API?

No public API is recorded for Equillium.

What industry is Equillium in?

Equillium's product category is Clinical-stage Immunotherapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comJefferies reiterates Equillium stock rating on clinical progressJefferies reiterated a Buy rating and $4 price target on Equillium after its EQ504 drug entered clinical trials, removing start-date risk. The stock trades at $1.32, down from a 52-week high of $3.54, with a consensus Buy and targets from $4 to $20. Next data is expected in Q2 2027, with a potential Phase 2 study in ulcerative colitis.Defense WorldEquillium (EQ) Projected to Post Earnings on ThursdayEquillium is expected to report Q3 2026 earnings after market close on November 12th, with analysts projecting a loss of $0.05 per share. The company previously beat estimates with a $0.04 loss in August, and analysts forecast a $0.21 loss for the current fiscal year. The stock opened at $1.46 with a market cap of $92.26 million.MarketBeatEquillium, Inc. (NASDAQ:EQ) Stock Has Consensus Target Price of $7.57Equillium's stock received a consensus Moderate Buy rating from 11 analysts, with an average 12-month price target of $7.57. The company reported Q2 EPS of -$0.04, beating the -$0.05 consensus, and its lead product itolizumab is being evaluated for autoimmune conditions.Ticker ReportContrasting Equillium (NASDAQ:EQ) and Grifols (NASDAQ:GRFS)Equillium and Grifols are compared on ratings, volatility, profitability, and ownership. Equillium has a higher consensus rating and potential upside, but Grifols shows stronger profitability and lower risk. Equillium beats Grifols on 8 of 15 factors.Ticker ReportLeerink Partners Initiates Coverage on Equillium (NASDAQ:EQ)Leerink Partners initiated coverage on Equillium with an outperform rating and a $6.00 price target, implying 354.55% upside. The stock opened at $1.32, and analysts have an average rating of Moderate Buy with a $7.57 target. Equillium reported a loss of $0.04 EPS for the quarter, beating estimates.American Banking and Market NewsLeerink Partners Initiates Coverage on Equillium (NASDAQ:EQ)Leerink Partners initiated coverage on Equillium with an outperform rating and a $6 price target, implying 321.35% upside. The stock closed at $1.42, and the consensus rating is Moderate Buy with a $7.57 target. Equillium reported a loss of $0.04 per share for the quarter.American Banking and Market NewsEquillium (NASDAQ:EQ) Given “Outperform” Rating at Leerink PartnersLeerink Partners reiterated an outperform rating on Equillium with a $6 price target, implying 325.53% upside. The stock opened at $1.41, and the company reported Q2 EPS of -$0.04, beating estimates. Analysts forecast a full-year loss of $0.21 per share.MarketBeatEquillium (NASDAQ:EQ) Given "Outperform" Rating at Leerink PartnersLeerink Partners restated an Outperform rating on Equillium with a $6.00 price target, implying 325.53% upside from the previous close. The stock opened at $1.41, and analysts forecast a -0.21 EPS for the current fiscal year. Institutional investors hold 27.05% of the company.Investing.comEquillium stock price target maintained at $20 by Piper SandlerPiper Sandler reiterated an Overweight rating and $20 price target on Equillium after the company received Australian regulatory clearance for its EQ504 drug candidate. The Phase 1 trial is expected to start in early November 2026, with proof-of-mechanism data anticipated in May 2027. A Phase 2 trial in ulcerative colitis is planned for the second half of 2027.Investing.comEquillium stock price target maintained at $20 by Piper SandlerPiper Sandler reiterated an Overweight rating and $20 price target on Equillium after the company received Australian regulatory clearance for its EQ504 drug candidate. The Phase 1 trial is expected to start in early November 2026, with proof-of-mechanism data anticipated in May 2027. The stock has declined 10% over the past week.